TOP1 and neoplasm: The total Top1 immunoassay has been transferred to the National Clinical Target Validation Laboratory, NCI (Bethesda, MD) to assess pharmacodynamic response in tumor biopsies in patient samples from current clinical trials of indenoisoquinoline Top1 inhibitors conducted at the NCI, and development of a Top1cc assay is in progress.